Professur für Innere Medizin (Nephrologie)

Criteria of the German Cardiac Society (DGK), the German Hypertension League DHL (R)/German Society for Hypertension and Prevention and the German Society for Nephrology (DGfN) on certification of renal denervation centers (RDZ)-Update (2021) Mahfoud F, Galle J, Schunkert H, Schmieder R, Rump LC, Limbourg FP, Van Der Giet M, et al. Journal article Responsiveness of afferent renal nerve units in renovascular hypertension in rats (2021) Rodionova K, Hilgers KF, Rafii-Tabrizi S, Doellner J, Cordasic N, Linz P, Karl A, et al. Journal article Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial (2021) Azizi M, Sanghvi K, Saxena M, Gosse P, Reilly JP, Levy T, Rump LC, et al. Journal article Serum markers of fibrosis, cardiovascular and all-cause mortality in hemodialysis patients: the AURORA trial (2021) Salib M, Girerd S, Girerd N, Marz W, Scharnagl H, Massy ZA, Leroy C, et al. Journal article Changes in Plasma Renin Activity After Renal Artery Sympathetic Denervation (2021) Mahfoud F, Townsend RR, Kandzari DE, Kario K, Schmieder R, Tsioufis K, Pocock S, et al. Journal article AT II Receptor Blockade and Renal Denervation: Different Interventions with Comparable Renal Effects? (2021) Rodionova K, Hindermann M, Hilgers KF, Ott C, Schmieder R, Schiffer M, Amann KU, et al. Journal article, Original article THE SGLT2 INHIBITOR EMPAGLIFLOZIN REDUCES TISSUE SODIUM CONTENT IN PATIENTS WITH CHRONIC HEART FAILURE (2021) Kolwelter J, Kannenkeril D, Linz P, Jung S, Nagel AM, Bosch A, Ott C, et al. Conference contribution EFFECTS OF THE SGLT2 INHIBITOR EMPAGLIFLOZIN ON VASCULAR FUNCTION IN PATIENTS WITH CHRONIC HEART FAILURE (2021) Kolwelter J, Bosch A, Jung S, Linz P, Kannenkeril D, Nagel AM, Ott C, et al. Conference contribution Mineralocorticoid receptor antagonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease (2021) Ortiz A, Ferro CJ, Balafa O, Burnier M, Ekart R, Halimi JM, Kreutz R, et al. Journal article EFFECTS OF FINERENONE ON CARDIORENAL OUTCOMES IN BLOOD PRESSURE SUBGROUPS IN PATIENTS WITH CKD AND T2D (2021) Ruilope L, Agarwal R, Anker SD, Filippatos G, Pitt B, Rossing P, Sarafidis P, et al. Conference contribution